Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:07:50 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ACAD - ACADIA PHARMACEUTICALS INC - http://www.acadia-pharm.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ACAD - Q0.416.00·18.500.116.71+0.402.51,168.218,8817,85216.45  16.74  16.26533.99  16.1619:10:12Apr 2415 min RT 2¢

Recent Trades - Last 10 of 7852
Time ETExPriceChangeVolume
19:10:12Q16.400.09200
19:02:14Q16.790.484
19:02:14Q16.800.4910
19:02:14Q16.950.64321
17:38:58Q16.700.3930
16:20:00Q16.710.40538
16:13:42Q16.710.4044
16:04:16Q16.700.39100
16:04:11Q16.410.101
16:02:20Q16.710.40682

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-24 16:05U:ACADNews ReleaseAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
2024-04-22 09:04U:ACADNews ReleaseAcadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
2024-04-19 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-17 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Presents New DAYBUE(TM) (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
2024-04-02 16:05U:ACADNews ReleaseAcadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
2024-04-01 16:05U:ACADNews ReleaseAcadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2024-03-15 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-13 16:05U:ACADNews ReleaseAcadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
2024-03-11 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
2024-02-29 09:05U:ACADNews ReleaseAcadia Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference on March 6, 2024
2024-02-27 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
2024-02-21 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-13 16:05U:ACADNews ReleaseAcadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
2024-01-30 20:48U:ACADNews ReleaseAcadia Announces Additions to Executive Team
2024-01-19 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-18 16:05U:ACADNews ReleaseAcadia Announces the Passing of Former President Srdjan (Serge) Stankovic
2023-12-21 16:05U:ACADNews ReleaseAcadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
2023-12-18 16:05U:ACADNews ReleaseAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-13 21:24U:ACADNews ReleaseDelaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID ‚ ® (pimavanserin)
2023-12-13 13:41U:ACADNews ReleaseDelaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID ‚ ® (pimavanserin) Patent Litigation